Physician profile
Amit Dua
NPI 1639131691
$7,512.66
in general payments reported to CMS, 2019-2025
44 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.77 · 2020: $439 · 2021: $1,873 · 2022: $1,060 · 2023: $1,538 · 2024: $1,691 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984 · Education: $87.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,983.62 |
| Education | $87.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Abbvie INC. | $971.15 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $790.24 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $665.38 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $529.60 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Paratek Pharmaceuticals, INC. | $392.63 | 2020-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $384.58 | 2021-2024 | |
| Lilly USA, LLC | $372.03 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $346.75 | 2021-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $215.84 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.96 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $151.56 | 2022 | |
| Pfizer INC. | $128.65 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $114.50 | 2021-2024 | |
| Lundbeck LLC | $97.52 | 2024-2025 | Rexulti |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.76 | 2024-2025 | Caplyta |
| Abbott Laboratories | $64.89 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $63.32 | 2020-2024 | |
| Dexcom, INC. | $61.07 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $55.97 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $51.47 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.56 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $46.20 | 2023-2024 | Livalo |
| Amgen INC. | $45.77 | 2022-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $39.74 | 2019-2025 | Gardasil 9, Capvaxive |
| Qol Medical, LLC | $36.62 | 2022-2023 | Sucraid |
| Medtronic, INC. | $35.94 | 2024 | Interstim |
| Corium, LLC | $35.90 | 2023 | Adlarity |
| Allergan, INC. | $32.63 | 2019-2020 | |
| Amarin Pharma, INC. | $29.35 | 2020-2021 | |
| Saluda Medical Americas, INC. | $27.20 | 2024 | Evoke |
| Acadia Pharmaceuticals INC | $23.91 | 2025 | Nuplazid |
| Philips North America LLC | $23.65 | 2024 | (Ck7) Extended Holter |
| Nevro Corp. | $23.41 | 2022 | |
| Inspire Medical Systems, INC. | $20.08 | 2025 | Inspire |
| Neurocrine Biosciences, INC. | $19.49 | 2023 | Ingrezza |
| Bausch Health US, LLC | $19.40 | 2022 | |
| Phadia US INC. | $16.87 | 2022 | |
| Boston Scientific Corporation | $15.97 | 2023 | Wavewriter Alpha Prime 16 |
| Linus Health, INC. | $15.95 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.64 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.24 | 2020 | |
| Exact Sciences Corporation | $13.17 | 2024 | Cologuard Collection Kit |
| Metacel Pharmaceuticals LLC | $6.10 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.